A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who completed the parent trial 1199.214/1199-0340 per protocol and did not permanently discontinue study treatment
Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly as well as one barrier method for 28 days prior to nintedanib treatment initiation, during the trial and for 3 months after last intake of nintedanib.
Further inclusion criteria apply
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
Bilirubin > 2 x ULN
Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula.
Clinically relevant anaemia at investigators discretion.
Bleeding risk, any of the following
Known genetic predisposition to bleeding according to the judgement of the investigator
Hemorrhagic central nervous system (CNS) event after completion of the parent trial 1199.214/1199-0340
Any of the following after last treatment of 1199.214/1199-0340:
Haemoptysis or haematuria
Active gastro-intestinal bleeding or Gastrointestinal (GI) - ulcers
Gastric antral vascular ectasia (GAVE)
Major injury or surgery
Coagulation parameters: International normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN at Visit 1.
New major thrombo-embolic events developed after completion of the parent trial 1199.214/1199-0340:
Deep vein thrombosis;
Major surgery performed within the next 3 months
Time period > 12 weeks between last drug intake in 1199.214 or > 1 week between last nintedanib intake in trial 1199-0340 and Visit 2 of this trial
Usage of any investigational drug after completion of 1199.214/1199-0340 or planned usage of an investigational drug during the course of this trial.
A disease or condition which may put the patient at risk because of participation in this trial (e.g. clinically relevant intestinal pseudoobstruction) or limit the patient's ability to participate in this trial
Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial
Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).
Women who are pregnant, nursing, or who plan to become pregnant while in the trial